[Efficacy of sublingual immunotherapy in children with dust mite allergic asthma]
- PMID: 20497640
[Efficacy of sublingual immunotherapy in children with dust mite allergic asthma]
Abstract
Objective: To compare the efficacy of sublingual immunotherapy (SLIT) combined with inhaled corticosteroids (ICS) versus ICS alone in children with mild and moderate dust mite allergic asthma.
Methods: Thirty-two children with mild and moderate dust mite allergic asthma were randomly divided into two groups: SLIT+ICS (n=18) and ICS alone (n=14). A total of 30 children completed the one year clinical observation . The amount of ICS administration, the day and night symptom scores, skin-prick test and pulmonary function test results, serum specific immunoglobulin E (sIgE) and G4 (sIgG4) levels and visual analog scale (VAS) scores were compared between the two groups.
Results: By the end of one year the SLIT+ICS group had significantly decreased amount of ICS administration than the ICS alone group. Compared with the ICS alone group, the day and night symptom scores decreased, FEF25-75% increased significantly, and serum sIgE levels and VAS scores were significantly reduced in the SLIT+ICS group. There were no statistical differences in the skin-prick test results, and FEV1 and sIgG4 levels between the two groups. No severe adverse events occurred in both groups during the follow-up period.
Conclusions: SLIT combined with ICS may produce a better efficacy than ICS alone in the improvement of day and night symptoms, pulmonary function and VAS scores in children with dust mite-allergic asthma.
Similar articles
-
Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.Pediatr Allergy Immunol. 2007 Feb;18(1):47-57. doi: 10.1111/j.1399-3038.2006.00475.x. Pediatr Allergy Immunol. 2007. PMID: 17295799 Clinical Trial.
-
Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.Pediatr Allergy Immunol. 2007 Sep;18(6):508-15. doi: 10.1111/j.1399-3038.2007.00549.x. Pediatr Allergy Immunol. 2007. PMID: 17680909 Clinical Trial.
-
Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.Clin Exp Allergy. 2010 Jun;40(6):922-32. doi: 10.1111/j.1365-2222.2009.03448.x. Epub 2010 Jan 20. Clin Exp Allergy. 2010. PMID: 20100188 Clinical Trial.
-
The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.Allergy. 2009 Nov;64(11):1570-9. doi: 10.1111/j.1398-9995.2009.02129.x. Epub 2009 Sep 30. Allergy. 2009. PMID: 19796205 Review.
-
[Preventive immunotherapy].Allergol Immunopathol (Madr). 2000 May-Jun;28(3):89-93. Allergol Immunopathol (Madr). 2000. PMID: 10867376 Review. Spanish.
Cited by
-
Effects of sublingual-specific immunotherapy on pulmonary function and exhaled nitric oxide levels in asthmatic children with and without allergic rhinitis.Transl Pediatr. 2020 Oct;9(5):686-694. doi: 10.21037/tp-20-322. Transl Pediatr. 2020. PMID: 33209732 Free PMC article.
-
Sublingual immunotherapy for asthma.Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD011293. doi: 10.1002/14651858.CD011293.pub3. Cochrane Database Syst Rev. 2020. PMID: 32926419 Free PMC article.
-
Progress in the management of childhood asthma.Asia Pac Allergy. 2012 Jan;2(1):15-25. doi: 10.5415/apallergy.2012.2.1.15. Epub 2012 Jan 31. Asia Pac Allergy. 2012. PMID: 22348203 Free PMC article.
-
Sublingual immunotherapy for asthma.Cochrane Database Syst Rev. 2015 Aug 28;2015(8):CD011293. doi: 10.1002/14651858.CD011293.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2020 Sep 14;9:CD011293. doi: 10.1002/14651858.CD011293.pub3. PMID: 26315994 Free PMC article. Updated.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical